251 related articles for article (PubMed ID: 33992829)
21. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
22. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
24. Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM; Sallman DA
Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
26. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
[TBL] [Abstract][Full Text] [Related]
27. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Gerds AT; Gooley TA; Estey EH; Appelbaum FR; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1211-8. PubMed ID: 22252125
[TBL] [Abstract][Full Text] [Related]
28. Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.
Guru Murthy GS; Zhang T; Bolon YT; Spellman S; Dong J; Auer P; Saber W
Biomark Res; 2024 Jan; 12(1):10. PubMed ID: 38273355
[TBL] [Abstract][Full Text] [Related]
29. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
Kharfan-Dabaja MA; Komrokji RS; Zhang Q; Kumar A; Tsalatsanis A; Perkins J; Nishihori T; Field T; Al Ali N; Mishra A; Sallman D; Salem KZ; Zhang L; Moscinski L; Fernandez HF; Lancet J; List A; Anasetti C; Padron E
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):753-758. PubMed ID: 28687222
[TBL] [Abstract][Full Text] [Related]
30. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic cell transplantation for myelodysplastic syndrome.
Deeg HJ
Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.
DeFilipp Z; Ciurea SO; Cutler C; Robin M; Warlick ED; Nakamura R; Brunner AM; Dholaria B; Walker AR; Kröger N; Bejanyan N; Atallah E; Tamari R; Solh MM; Percival ME; de Lima M; Scott B; Oran B; Garcia-Manero G; Hamadani M; Carpenter P; DeZern AE
Transplant Cell Ther; 2023 Feb; 29(2):71-81. PubMed ID: 36436780
[TBL] [Abstract][Full Text] [Related]
33. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
35. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
36. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
37. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.
Yeung CCS; Gerds AT; Fang M; Scott BL; Flowers MED; Gooley T; Deeg HJ
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1565-1575. PubMed ID: 25953732
[TBL] [Abstract][Full Text] [Related]
38. Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation.
Langston JA; Sundaram V; Periyakoil VS; Muffly L
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1659-1665. PubMed ID: 30959162
[TBL] [Abstract][Full Text] [Related]
39. Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.
Gerds AT; Deeg HJ
Curr Opin Hematol; 2012 Mar; 19(2):71-5. PubMed ID: 22227527
[TBL] [Abstract][Full Text] [Related]
40. Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome.
Danielson N; Byrne M
Curr Hematol Malig Rep; 2020 Aug; 15(4):268-275. PubMed ID: 32125608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]